Sugammadex Versus Neostigmine for Recovery of Respiratory Muscle Strength Measured by Ultrasonography in the Postextubation Period: A Randomized Controlled Trial
Primary resultResult — go to the resultDifference in means −6% 95% CI −10 to −2Authors' conclusion
Sugammadex provides a more complete recovery of expiratory muscle strength than neostigmine at TOFR ≥0.9.
Study context
- Population
- Adults having microlaryngeal surgery under TIVA
- Participants
- 58 adults
- Comparison
- Sugammadex vs neostigmine for NMB reversal
- Primary endpoint
- Change in thickening fraction of internal oblique abdominal muscle (TF IO, expiratory muscle strength, ultrasonography) from baseline
- Follow-up
- TOFR ≥0.9
Primary result
As reported in the abstract
Difference in means
−6%
95% CI −10 to −2
P = 0.005
By group
Sugammadex vs Neostigmine
difference in means −6% (95% CI −10 to −2); P = 0.005
Further findings
| Outcome | Difference in means (cm) (99.4% CI) | P value | |
|---|---|---|---|
| Change in diaphragm excursion from baseline · TOFR ≥0.9Bonferroni-corrected | −0.83 (−1.39 to −0.28 cm) | P < 0.001 | |
| −2−101Difference, cm (linear scale) |
Reached baseline TF IO · 30 minutes after PACU arrival · Bonferroni-corrected
(99.4% CI −14 to 52) · P > 0.999
Time from TOFR 0.9 to 0.95 · Bonferroni-corrected
P = 0.003
Time from TOFR 0.9 to 1 · Bonferroni-corrected
P < 0.001
Reached baseline TF IO · 30 minutes after postanesthesia care unit (PACU) arrival
- Incidences of TF IO and diaphragm excursion returning to baseline relatively low (<40%) in both groups despite train-of-four ratio (TOFR) reaching 1
Original publication
Sugammadex Versus Neostigmine for Recovery of Respiratory Muscle Strength Measured by Ultrasonography in the Postextubation Period: A Randomized Controlled Trial. Anesth Analg. Published 24 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →